Skip to content
TrialScanner

NCT06157151

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2RecruitingPGENLead

Registry record

Lead sponsor
Precigen, Inc
Conditions
Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metastatic Cervical Cancer
Primary completion
Nov 11, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT06157151 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06157151: PRGN-2009 in Combination... | TrialScanner